Table 3.
Unadjusted Annual Rates of Influenza Vaccination, Mammography, and Diabetes Care Measures by Cancer/Control Status and Year/Phase
| Observation Year | Phase before Diagnosis |
Phase after Initial Treatment |
Surveillance Phase |
Survival Phase |
||||
|---|---|---|---|---|---|---|---|---|
| −1 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | |
| Influenza vaccination* | ||||||||
| Stage 0–1 CRC cases† | 50.9 (49.6–52.1) | 53.2 (52.0–54.4) | 53.9 (52.5–55.3) | 51.9 (50.2–53.6) | 52.6 (49.5–53.7) | 52.4 (49.5–55.3) | 52.5 (47.0–58.0) | |
| Stage 2–3 CRC cases‡ | 46.4 (45.4–47.4) | 50.2 (49.1–51.2) | 49.9 (48.7–51.1) | 49.3 (47.8–50.8) | 47.5 (45.5–49.4) | 49.2 (46.5–51.9) | 51.1 (46.2–56.0) | |
| Controls§ | 46.1 (45.7–46.5) | 47.0 (46.6–47.4) | 47.6 (47.1–48.0) | 48.0 (47.4–48.5) | 48.1 (47.4–48.7) | 45.9 (45.0–46.8) | 48.3 (46.7–49.9) | |
| Mammography|| | ||||||||
| Stage 0–1 CRC cases¶ | 41.6 (39.1–44.1) | 45.0 (42.5–47.5) | 43.6 (40.7–46.6) | 48.0 (44.3–51.8) | 49.6 (44.7–54.5) | 52.4 (44.7–58.2) | 52.4 (41.7–63.1) | 50.0 (25.5–74.5) |
| Stage 2–3 CRC cases** | 31.4 (29.4–33.4) | 40.2 (38.1–42.3) | 44.3 (41.5–47.0) | 46.2 (42.7–49.7) | 46.6 (41.8–51.4) | 52.5 (45.6–59.5) | 52.9 (42.3–63.6) | 62.5 (38.8–86.2) |
| Controls†† | 38.6 (37.9–39.2) | 40.5 (39.8–41.2) | 41.1 (40.3–41.9) | 42.5 (41.5–43.4) | 42.5 (41.3–43.8) | 44.2 (42.6–45.9) | 44.4 (41.8–47.0) | 43.2 (37.3–49.1) |
| HgbA1c testing (among diabetics)‡‡ | ||||||||
| Stage 0–1 CRC cases§§ | 55.9 (53.0–58.7) | 60.1 (57.3–62.9) | 64.1 (60.9–67.2) | 64.3 (60.2–67.9) | 66.8 (62.2–71.3) | 70.1 (64.6–75.7) | 73.6 (66.7–80.4) | 67.9 (57.7–78.1) |
| Stage 2–3 CRC cases|||| | 53.4 (51.0–55.8) | 54.9 (52.5–57.3) | 59.4 (56.5–62.2) | 60.4 (56.9–63.8) | 64.4 (60.1–68.6) | 62.7 (57.2–68.1) | 62.5 (55.2–69.8) | 72.1 (61.4–82.7) |
| Controls¶¶ | 53.7 (52.6–54.7) | 58.7 (57.7–59.7) | 61.2 (60.0–62.2) | 62.9 (61.6–64.2) | 64.6 (63.1–66.1) | 66.1 (64.2–67.9) | 66.5 (64.2–68.9) | 67.8 (64.6–71.1) |
| Serum lipid measurements (among diabetics)*** | ||||||||
| Stage 0–1 CRC cases††† | 57.3 (54.4–60.2) | 52.8 (50.0–55.7) | 57.6 (54.3–60.8) | 53.6 (49.6–57.6) | 57.1 (52.4–61.9) | 60.5 (54.6–66.5) | 59.8 (52.1–67.4) | 59.3 (48.6–70.0) |
| Stage 2–3 CRC cases‡‡‡ | 51.0 (48.6–53.4) | 47.9 (45.5–50.3) | 48.6 (45.7–51.5) | 50.6 (47.1–54.1) | 52.1 (47.7–56.6) | 54.7 (49.0–60.3) | 51.8 (44.2–59.3) | 48.5 (46.7–60.4) |
| Controls§§§ | 52.6 (51.6–53.7) | 53.2 (52.1–54.2) | 54.4 (53.2–55.5) | 55.5 (54.2–56.8) | 57.9 (56.3–59.4) | 57.5 (55.6–59.4) | 58.5 (56.0–61.0) | 61.3 (57.9–64.7) |
Values provided as % (CI).
Difference in trend in receipt of influenza vaccination between stage 0–1 CRC cases and controls is nonsignificant, between stage 2–3 CRC cases and controls, P ≤ .001; between stage 0–1 and stage 2–3, P ≤ .05.
Test for trend in receipt of influenza vaccination over time for stage 0–1 CRC cases is nonsignificant.
Test for trend in receipt of influenza vaccination over time for stage 2–3 CRC cases, P ≤ .001.
Test for trend in receipt of influenza vaccination over time for controls, P ≤ .01.
Difference in trend in receipt of mammography between stage 0–1 CRC cases and controls is nonsignificant; between stage 2–3 CRC cases and controls, P ≤ .001; between stage 0–1 and stage 2–3, P ≤ .05.
Test for trend in receipt of mammography over time for stage 0–1 CRC cases, P ≤ .001.
Test for trend in receipt of mammography over time for stage 2–3 CRC cases, P ≤ .001.
Test for trend in receipt of mammography over time for controls, P ≤ .001.
Difference in trend in HgbA1c testing between stage 0–1 CRC cases and controls is nonsignificant; between stage 2–3 CRC cases and controls is nonsignificant; and between stage 0–1 and stage 2–3 is nonsignificant.
Test for trend in HgbA1c testing over time for stage 0–1 CRC cases, P ≤ .001.
Test for trend in HgbA1c testing over time for stage 2–3 CRC cases, P ≤ .001.
Test for trend in HgbA1c testing over time for controls, P ≤ .01.
Difference in trend in lipid testing between stage 0–1 CRC cases and controls is nonsignificant; between stage 2–3 CRC cases and controls, P ≤ .05; between stage 0–1 and stage 2–3 is nonsignificant.
Test for trend in lipid testing over time for stage 0–1 CRC cases is nonsignificant.
Test for trend in lipid testing over time for stage 2–3 CRC cases is nonsignificant.
Test for trend in lipid testing over time for controls, P ≤ .001.
CRC, colorectal cancer; HgbA1c, hemoglobin A1c or glycosylated haemoglobin.